Atossa Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
The Vanguard Group reported a 4.51% beneficial ownership stake in Atossa Therapeutics Inc. as of June 30, 2025.
NASDAQ
SCHEDULE 13G/A: BlackRock Discloses 1.6% Passive Stake in Atossa Therapeutics
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 1.6% beneficial ownership stake in Atossa Therapeutics, Inc.'s common stock as of June 30, 2025.
NASDAQ
CVI Investments, Inc. and Heights Capital Management, Inc. have disclosed a passive 4.3% beneficial ownership stake in Atossa Therapeutics, Inc. as of December 31, 2024.